Key facts
- Zumutor Biologics’s last known valuation is $42.6M (Apr 2025).
- It has raised $29.1M; the latest was Later Stage VC ($3.1M) in Apr 2025.
- Notable investors include Accel, Madison India Capital, 3iPartners, Aarin Capital, Bharat Innovation Fund — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Zumutor Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Zumutor Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zumutor Biologics
Operator of an immuno-oncology company intended to offer targeted cell therapeutics. The company develops diverse human antibody libraries to identify novel Immunotherapies and improved monoclonal antibodies and targets certain receptors that block NK cell inhibitory signals and allow NK cell activation to generate a potent immune response, enabling clinicians to get novel immunotherapies that target innate immunity and regulate the tumor microenvironment.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2013
- Employees
- 26
- Website
- zumutor.com/
- Ownership
- Privately Held (backing)
Zumutor Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zumutor Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zumutor Biologics in its N-PORT filings yet. We sweep new filings monthly.